Invokana, Farxiga, Jardiance Get Ketoacidosis, Urinary Tract Infection Warnings

(December 21, 2015, 12:00 PM EST) -- SILVER SPRING, Md. — The Food and Drug Administration on Dec. 4 said a safety review of sodium-glucose cotransporter-2 (SGLT2) inhibitors has resulted in new label warnings about the risk of excess acid in the blood and of serious urinary tract infections, both of which can result in hospitalization....

Related Sections